Hypoactive Sexual Desire Disorder Clinical Trial
Official title:
Pilot Study: Evaluating the Effect of 300 Micrograms Testosterone Patches in Addition to Hormone Replacement Therapy on Arterial Compliance, Insulin Resistance and Sexual Desire.
The purpose of this study is to examine the effect of the testosterone patch, in addition to hormone replacement therapy (HRT), on blood vessel walls, insulin levels and sexual desire.
A woman's ovaries produce the hormone testosterone during her reproductive life but
testosterone levels decline with age or when the ovaries are removed. Testosterone has been
associated with sexual desire in both men and women. Low testosterone is also believed to
cause symptoms of low energy. Thus testosterone is increasingly used in hormone replacement
regimens to restore libido and energy in postmenopausal women.
In the past testosterone has been administered orally or via subcutaneous implants. Recently
testosterone patches have been licensed for treating low libido in postmenopausal women. The
testosterone patches deliver a dose of testosterone equivalent to the levels produced by the
ovary during a woman's early reproductive years.
Oral testosterone can lead to changes to insulin and cholesterol levels which increase the
risk of heart disease. On the contrary, testosterone patches may reduce or avoid this risk.
To date, trials have predominantly focused on safety data in terms of side effects and basic
blood tests. Reviews of the safety of testosterone replacement have emphasised the need for
improved safety data, especially in terms of cardiovascular risk.
The investigators hypothesis that transdermal testosterone, in addition to HRT, will have no
adverse effects on blood vessel walls and insulin levels and that transdermal testosterone
significantly improves sexuality and psychological well-being in postmenopausal women.
Trial design:
The investigators aim to recruit 20 postmenopausal women to wear the testosterone patch for 3
months in addition to their usual hormone replacement therapy.
There will be 3 study visits - a pre study visit, week 6 and week 12. At each visit the
following procedures will be performed:
- Medical history and physical examination
- Blood sample - for hormone levels, lipids and insulin levels
- Blood vessel stiffness measurements This will be performed using a small ultrasound
device at the wrist with blood pressure measured every 5 minutes.
- Endothelial function (function of your arterial wall) is measured using a blood pressure
cuff on each arm and finger probes on one finger of each hand. The blood pressure cuff
is inflated for 5 minutes and is then deflated quickly. The finger probes will record
the readings throughout this study.
- Sexual satisfaction questionnaire
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02430987 -
Low Sexual Desire and Metabolic Syndrome
|
N/A | |
| Completed |
NCT01432665 -
Lybrido for Female Sexual Dysfunction
|
Phase 2 | |
| Terminated |
NCT00551785 -
Surveillance Study of Women Taking Intrinsa®
|
Phase 4 | |
| Completed |
NCT03232801 -
A Mindfulness-based Intervention for Older Women With Low Sexual Desire
|
N/A | |
| Recruiting |
NCT04179734 -
Role of the Melanocortin-4 Receptor in Hypoactive Sexual Desire Disorder
|
Phase 4 | |
| Active, not recruiting |
NCT02770768 -
Effects of Flibanserin on the Pre- and Post-menopausal Female Brain
|
N/A | |
| Completed |
NCT01235754 -
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)
|
Phase 3 | |
| Completed |
NCT03287232 -
Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)
|
Phase 3 | |
| Completed |
NCT00384046 -
Testosterone Therapy in Naturally Menopausal Women With Low Sexual Desire Receiving Transdermal Estrogen
|
Phase 3 | |
| Completed |
NCT00331123 -
Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido
|
Phase 3 | |
| Recruiting |
NCT04943068 -
A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal)
|
Phase 3 | |
| Completed |
NCT03463707 -
BP101 for Adults With Female Sexual Dysfunction
|
Phase 3 | |
| Completed |
NCT00657501 -
Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
|
Phase 3 | |
| Completed |
NCT04336891 -
Effect of Testosterone Treatment on Clitoral Arteries' Hemodynamic Parameters.
|
||
| Completed |
NCT01382719 -
Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder
|
Phase 2 | |
| Recruiting |
NCT00916396 -
Dehydroepiandrosterone (DHEA) Treatment in Women and Men Experiencing Hypoactive Sexual Desire Disorder
|
N/A | |
| Completed |
NCT00338312 -
Study of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido
|
Phase 3 | |
| Completed |
NCT00331214 -
Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido
|
Phase 3 | |
| Completed |
NCT00034021 -
Ginkgo Biloba: Antidepressant-Induced Sexual Dysfunction
|
Phase 2 | |
| Recruiting |
NCT02968342 -
Role of Progesterone in Hypoactive Sexual Desire Disorder in Menopausal Women
|
Phase 4 |